Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp188 | Genetics | ECTS2014

Correlation of miRNA-mRNA regulatory network profile with bone mass in inbred strains of mice

Shin Chansoo , An Jee Hyun , Song Jung A , Yang Jae-Yeon , Choi Hyung Jin , Kim Sang Wan

Growing body of evidence shows that microRNAs play an important role in regulating bone mass. We investigated the cooperative microRNA-mRNA regulatory mechanism of peak bone mass in inbred strain of mice with different bone density using microarray analysis. Femur and tibia of 12-week old C3H/He (high bone density) and C57BL/6 (low bone density) were harvested to extract total bone RNAs for microarray. A total of 30 miRNAs were differentially expressed between bone tissue of C...

ba0003pp306 | Osteoporosis: treatment | ECTS2014

The effect of bisphosphonate treatment on sclerostin levels in postmenopausal osteoporosis: the TRIO study

Gossiel Fatma , Naylor Kim , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Paggiosi Margaret , Eastell Richard

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...

ba0003pp330 | Osteoporosis: treatment | ECTS2014

Determinants of bone turnover marker response to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Naylor Kim , Paggiosi Margaret , Gossiel Fatma , McCloskey Eugene , Peel Nicola , Walsh Jennifer , Eastell Richard

Three oral bisphosphonates ibandronate, alendronate, and risedronate are commonly used for the treatment of osteoporosis but they have not previously been compared in the same study. Our aim was to identify determinants of change in bone turnover markers (BTM) in response to these bisphosphonates in a 2-year randomised parallel group trial. We recruited 171 postmenopausal osteoporotic women (<85 years) who were randomised to receive ibandronate (150 mg monthly), alendronat...

ba0003pp400 | Other diseases of bone and mineral metabolism | ECTS2014

Pseudoseptical myositis as the prodrome of myositis ossificans

Shin Myung Jun , Jeon Yun Kyung , Park Yeo Jin , Kim Seong-Jang , Shin Yong Beom

A 20-year-old male presented following a fall down. He was diagnosed with a C5–C7 burst fracture and underwent a cervical fixation surgery. He was transferred to inpatient rehabilitation with C6 ASIA A tetraplegia.70 days after the operation, he began to have intermittent mild fever with a temperature of 37.4 oC. On postoperative day 72, left thigh was noted to be edematous. The circumferential difference between the lower extremities mea...

ba0003pp404 | Other diseases of bone and mineral metabolism | ECTS2014

Effects of up to 15 years of recombinant human GH replacement therapy on the skeleton in adult GH deficiency: the Leiden Cohort Study

Appelman-Dijkstra Natasha , Claessen Kim , Hamdy Neveen , Pereira Alberto , Biermasz Nienke

Background: Adult GH Deficiency (GHD) is associated with decreased bone mass and increased fracture risk. Recombinant human GH (rhGH) replacement therapy leads to progressive increases in bone mineral density (BMD) for up to 7 years of treatment, but little is known on longer term effects of rhGH therapy on bone mass or fracture risk.Methods: 230 GHD patients (mean age 47.1 years, 52.6% female) on rhGH replacement therapy for ≥5 years were included...

ba0004p127 | (1) | ICCBH2015

The outcomes of a standardized approach to managing metabolic bone disease of prematurity

Chin Lit Kim , Doan John , Teoh Yvonne Sui Lien , Stewart Alice , Forrest Peter , Simm Peter J

Metabolic bone disease (MBD) of prematurity is a well-recognized complication of preterm birth. Yet there is limited evidence for the optimal assessment, monitoring, and subsequent bone health management.Retrospective audit of 171 infants born <32 weeks’ gestation between November 2012 and January 2014 at three Monash Health neonatal units (Melbourne, Australia) was undertaken. Infants had mean gestational age (GA) 28.6±2.1 weeks and birth ...

ba0005oc3.4 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis

Gossiel Fatma , McCloskey Eugene , Walsh Jennifer , Naylor Kim , Peel Nicola , Eastell Richard

FGF-23 is a phosphate regulating hormone and its production may be stimulated by circulating levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D). Teriparatide administration increases levels of 1,25-(OH)2D, however it is unclear whether this mediates changes in FGF-23 levels. The aims were i) to determine the effect of teriparatide treatment on circulating levels of FGF-23 and 1,25-(OH)2D and ii) to describe the time course of effect in postmenopau...

ba0005oc6.4 | Development and differentiation (or Aging) | ECTS2016

Extranuclear effects of estrogen on cortical bone in males is dependent on estrogen receptor A activation function-1

Farman Helen , Wu Jianyao , Gustafsson Karin , Windahl Sara , Kim Sung , Katzenellenbogen John , Ohlsson Claes , Lagerquist Marie

Estradiol (E2) signaling via estrogen receptor alpha (ERα) is important for the male skeleton as demonstrated by ERα inactivation in both mice and man. ERα mediates estrogenic effects by translocating to the nucleus and there affects gene transcription, but some effects can also be mediated via extra-nuclear actions of the receptor by, e.g., triggering cytoplasmic signaling cascades. ERα contains various domains and the role of activation functio...

ba0005p192 | Cell biology: osteoclasts and bone resorption | ECTS2016

Regulation and function of lentiviral-mediated TCIRG1 expression in osteoclasts from infantile malignant osteopetrosis patients

Lofvall Henrik , Thudium Christian Schneider , Moscatelli Ilana , Montano Carmen , Schulz Ansgar , Richter Johan , Henriksen Kim

Infantile malignant osteopetrosis (IMO) is a rare, lethal, recessive disorder characterized by dysfunctional osteoclasts. TCIRG1, encoding the osteoclast V-ATPase, is mutated in 50% of IMO patients. We have previously shown that the resorptive function in osteoclasts derived from IMO patients can be restored in vitro by expressing TCIRG1 using a lentiviral vector. In this study, we aim to investigate the cellular response to vector-derived TCIRG1 expression and to det...

ba0005p282 | Nutrition | ECTS2016

Waist-to-height ratio (WHtR) and coronary artery calcification

Song Sang-Wook , Kim Jeoung-Ah , Kang Sung-Goo , Yum Keun Sang

Background: Many studies have demonstrated that waist-to-height ratio (WHtR) correlates with risk factors of coronary artery disease (CAD) better, than the body mass index (BMI). Coronary artery calcification (CAC) is an independent risk factor of atherosclerotic heart disease. However, the association between WHtR and coronary artery calcification scores (CACS) still need to be elucidated. The purpose of this study was to investigate the relationship between WHtR and CACS in ...